WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003057907) EXPRESSION AND PURIFICATION OF ATM PROTEIN USING VACCINIA VIRUS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/057907    International Application No.:    PCT/US2002/041598
Publication Date: 17.07.2003 International Filing Date: 23.12.2002
IPC:
C07K 14/47 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; Office of Technology Transfer 1111 Franklin Street, Fifth Floor Oakland, CA 94607 (US) (For All Designated States Except US).
GATTI,, Richard, A. [US/US]; (US) (For US Only).
CHUN, Helen, H. [US/US]; (US) (For US Only).
RAWLINGS, David, J. [US/US]; (US) (For US Only)
Inventors: GATTI,, Richard, A.; (US).
CHUN, Helen, H.; (US).
RAWLINGS, David, J.; (US)
Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson And Bear, LLP 2040 Main Street, Fourteenth Floor Irvine, CA 92614 (US)
Priority Data:
10/042,775 08.01.2002 US
Title (EN) EXPRESSION AND PURIFICATION OF ATM PROTEIN USING VACCINIA VIRUS
(FR) EXPRESSION ET PURIFICATION DE LA PROTEINE ATM A L'AIDE DU VIRUS DE LA VACCINE
Abstract: front page image
(EN)The present disclosure concerns methods for recombinantly producing functional ataxia-telangiectasia (ATM) protein, methods for isolating recombinant functional ATM protein, and uses of ATM protein. In particular, a method is disclosed for using a vaccinia virus vector to express ATM, and using immunoprecipitation or affinity tagging to isolate recombinant ATM.
(FR)La présente invention concerne des procédés de production par recombinaison de la protéine fonctionnelle ataxia-telangiectasia (ATM), des procédés d'isolation de la protéine fonctionnelle ATM de recombinaison isolée, et les utilisations de la protéine ATM. L'invention concerne en particulier un procédé pour utiliser un vecteur viral de la vaccine pour exprimer l'ATM, et pour mettre en oeuvre l'immunoprécipitation ou le marquage d'affinité pour isoler l'ATM de recombinaison.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)